But on Friday, 01-21, the Wall Street Journal’s Nathan Koppel broke the news that Hospira Inc., based in Lake Forest, Ill., has decided to permanently halt production of thiopental sodium, a key drug widely used by states in lethal injections.
Hospira’s decision puts a wrench in the nation’s capital-punishment system. States can attempt to use another anesthetic in place of thiopental, but such a switch likely would need to be approved by courts and possibly state legislators.
Many states have already run out of thiopental, forcing prison officials to delay executions. The drug shortage followed a 2009 decision by Hospira to suspend production due to manufacturing issues.
The Lake Forest, Ill., company had planned to resume producing thiopental in the first quarter of 2011 at a company plant in Liscate, Italy. But in December, the Italian parliament issued an order binding the government to ensure that Hospira’s Italian-made thiopental would not be used in lethal injections.
In the face of that opposition, Hospira ultimately decided to exit the thiopental market, said company spokeswoman Tareta Adams. “This will be a challenge for [medical] customers and we regret that,” Ms. Adams said. “But we don’t want to put our Italian facility at risk that the product will be misused” by U.S. prisons.